CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 No DAC & Ipamorelin Results Timeline: Sleep and Recovery Research

Real Peptides Research TeamEditorial

Updated April 27, 202610 min read

60 WORDS

Short answer

Key takeaways

No validated CJC-1295 no DAC and Ipamorelin results timeline exists in the literature reviewed here — for sleep, recovery, or body composition. Human data on the pairing is thin, and the week-by-week numbers in circulation are not trial-derived.
The described mechanism is pituitary GH secretion through GHRH and ghrelin receptors, not sedation; neither compound is characterised as a central nervous system depressant.
Mechanistically, sleep-architecture markers sit upstream of body-composition markers, which is why endocrine research treats them on different timescales.
Baseline cortisol and baseline endogenous GH output are the variables most often cited as sources of between-subject variability in GH secretagogue research generally.
Polysomnography, actigraphy, salivary cortisol, and serial IGF-1 are the instruments that would quantify any effect; magnitudes for this combination are not specified in the sources available.
Ipamorelin's selectivity for GHS-R1a — sparing cortisol and prolactin relative to earlier GHRPs — is a compound-specific pharmacological property, distinct from any sleep outcome.

The literature reviewed for this article does not establish a validated results timeline for CJC-1295 no DAC combined with Ipamorelin — not for sleep, not for recovery, not for body composition. No controlled human trial tracking this specific pairing week by week with polysomnography or recovery markers is cited on this page, and the interval at which any measurable change would appear is not specified in the available sources. The week-by-week figures that circulate for this combination come from anecdote rather than from trial data, and this page does not reproduce them as if they were measured outcomes.

What the pharmacology does describe is the order in which the two compounds act. CJC-1295 without DAC is a modified GHRH (growth hormone-releasing hormone) analogue that binds GHRH receptors on the anterior pituitary; lacking the drug affinity complex that keeps the DAC version bound to plasma proteins for days, it is short-acting by design. Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist that acts on the same secretory event from a different receptor. Because both converge on the growth hormone pulse, a GH signal in research models is a same-session measurement, while IGF-1 (insulin-like growth factor 1) — the downstream mediator — is a slower marker that GH research generally tracks across days to weeks. That is mechanistic reasoning about the compound class, clearly labeled as such, not a measured timeline for this pairing.

Human evidence on the combination is thin, and it is worth saying so plainly. The sleep- and recovery-specific claims attached to CJC-1295 no DAC and Ipamorelin in consumer material are not supported by any citation carried on this page. These compounds are supplied for research use only and are not for human consumption.

What does the CJC-1295 no DAC & Ipamorelin results timeline look like in the research?

The timeline has not been characterised for this pair. What research design would answer the question is clear enough: polysomnography for slow-wave and REM proportions, actigraphy or wearable data for wake episodes and sleep efficiency, salivary or serum cortisol for HPA output, and serial IGF-1 for downstream GH signalling. Those are the instruments sleep and endocrine studies use. The relevant background biology is also well described in general endocrinology: a nocturnal GH pulse follows sleep onset in healthy adults and its amplitude declines progressively with age. Whether these two peptides restore that pulse on a predictable schedule is not something the literature reviewed here specifies.

One misconception is worth correcting at the mechanism level: the pathway involved is pituitary GH secretion via GHRH and ghrelin receptors, not the GABAergic or melatonergic pathways that sedatives and sleep aids act on. Neither compound is described in the literature as a sedative. The rest of this article covers which markers move quickly and which move slowly in GH research, how cortisol and GH interact, and why baseline endocrine status is the main source of variability between research subjects.

Week-by-Week Timeline: Which Markers Research Tracks, and When

The first window is pharmacodynamic. CJC-1295 no DAC binds GHRH receptors in the anterior pituitary, amplifying pulse amplitude without the plasma binding that extends half-life in the DAC version. Ipamorelin activates GHS-R1a selectively, and the selectivity is the point: unlike GHRP-6 and GHRP-2, it is described in the peptide literature as sparing cortisol and prolactin release. Used together, the two are characterised mechanistically as complementary — one acting on pulse amplitude, the other on pulse frequency. This is compound-class pharmacology, not a sleep outcome.

The variable that research would expect to move first is not total sleep time but sleep architecture — the proportion of the night spent in each stage, plus the number of wake episodes. The mechanistic rationale is the reciprocal relationship between GH and cortisol: growth hormone exerts negative feedback on the hypothalamic-pituitary-adrenal (HPA) axis, and the early-morning cortisol rise is a recognised contributor to sleep fragmentation in adults. The magnitude of any cortisol change attributable to this peptide combination is not specified in the literature reviewed here.

The middle window is where sleep architecture becomes measurable at all. Polysomnography is the method used to quantify Stage 3 slow-wave sleep (SWS), the deepest non-REM phase and the stage during which endogenous GH secretion naturally peaks. SWS is associated in sleep physiology with cellular repair, immune signalling, and memory consolidation. The mechanistic proposition for GH secretagogues is a shift in the ratio of restorative to light sleep rather than an increase in total sleep duration — but no polysomnography trial of CJC-1295 no DAC with Ipamorelin is cited on this page, so no percentage shift should be attributed to the pair.

The later window is where IGF-1 becomes informative, since it reaches steady state more slowly than any single GH pulse. IGF-1 also interacts with circadian regulation through the suprachiasmatic nucleus (SCN), the master clock — again, general endocrine physiology rather than a finding about this combination. Sleep latency and sleep efficiency (time asleep divided by time in bed) are the endpoints such research would report. This page carries no citation for a controlled trial measuring those endpoints with these two compounds.

The Cortisol–GH Relationship: Why Sleep Markers Move Before Body-Composition Markers

Growth hormone and cortisol operate in reciprocal feedback: elevated cortisol suppresses GH secretion, and elevated GH suppresses cortisol output. This is the mechanistic reason chronically stressed populations are described in the endocrine literature as showing both disrupted sleep and impaired fat oxidation. Cortisol promotes gluconeogenesis (glucose production from amino acids) and restrains lipolysis (triglyceride breakdown), biasing metabolism toward glucose availability.

The proposed mechanism for GH secretagogues runs in the opposite direction. GH binds receptors in adipose tissue and activates hormone-sensitive lipase (HSL), the enzyme releasing stored triglycerides into circulation, while simultaneously dampening ACTH (adrenocorticotropic hormone) release from the pituitary. Restoration of the nocturnal pulse — which peaks after sleep onset in healthy adults and diminishes after roughly age 30 — is the hypothesised entry point. Whether CJC-1295 no DAC and Ipamorelin achieve that restoration in humans is not documented in the sources cited here.

Sequence, in mechanistic terms, is why sleep-related markers are the upstream measurement and body-composition markers the downstream one. Fat oxidation requires sustained hormonal change; a single night of altered sleep architecture does not mobilise meaningful fat mass. Research that pairs wearable sleep data with DEXA body-composition scans is designed to separate those two timescales. The lag between them for this peptide pair has not been quantified in the literature reviewed here.

We have followed this progression across the peptide literature rather than in controlled trials of the combination, and the most common error in consumer write-ups is presenting metabolic change as immediate. These are not stimulants; they act on hormonal signalling, and hormonal signalling is measured over weeks.

CJC-1295 No DAC & Ipamorelin Results Timeline: Research Profiles Compared

Research Profile	Baseline Pattern Described	Early-Window Variables Measured	Later-Window Variables Measured	Confounder Noted
High-stress adult, elevated evening cortisol	Frequent waking, extended sleep latency, reduced slow-wave sleep	Salivary cortisol curve, wake-episode count	Sleep efficiency, REM duration	Ongoing stress exposure alters HPA output independently; effect size for this combination not specified in the literature reviewed here
Aging adult (>45, declining endogenous GH)	Shallow sleep, early waking, daytime fatigue	Nocturnal GH pulse amplitude	IGF-1 steady state, slow-wave sleep share	Pituitary responsiveness to GHRH and ghrelin mimetics declines with age (general endocrinology, not compound-specific)
Athlete with overtraining markers	Difficulty initiating sleep despite fatigue, elevated resting heart rate	Resting heart rate, HRV, sleep onset latency	Recovery markers, sleep efficiency	Training load is the dominant variable; no cited trial isolates a peptide effect from load management
Shift worker or irregular schedule	Fragmented circadian rhythm, inconsistent night-to-night quality	Actigraphy consistency, wake-episode count	Circadian phase markers	Circadian disruption is an independent driver and is not controlled for in available reports

What If: Research Scenarios for CJC-1295 No DAC & Ipamorelin Timelines

What the Literature Describes When No Change Appears in an Early Observation Window

Absence of an early signal is consistent with several explanations, none of which the cited literature resolves. Elevated baseline cortisol can mask GH-related changes in subjective sleep reports, since HPA output is driven by inputs unrelated to the compounds. Subjective sleep reports are also a noisy endpoint; polysomnography and actigraphy exist because self-report and measured sleep architecture diverge. The literature reviewed here does not specify how long a GH-related change in sleep staging would take to become detectable with this combination.

What Research Notes About Deep Sleep Without Proportional REM

Sleep physiology describes grogginess on waking as associated with slow-wave sleep occurring late in the sleep period rather than during the first cycles, when SWS naturally predominates. That is a general sleep-architecture observation, not a finding about CJC-1295 no DAC or Ipamorelin, and no cited study has measured stage distribution under this combination. Wearable and polysomnographic data are the measurements that distinguish a stage-distribution pattern from other causes of morning sluggishness.

What Is Known About Melatonin Alongside CJC-1295 and Ipamorelin

Melatonin acts on circadian timing through melatonin receptors; the GH secretagogue pathway is separate. Interaction data for melatonin taken alongside this peptide combination is not specified in the literature reviewed here, and claims that particular melatonin amounts blunt or enhance GH secretagogue activity are not supported by any citation carried on this page. The honest position is that the interaction has not been characterised in the sources available.

The Unvarnished Truth About CJC-1295 No DAC & Ipamorelin Sleep and Recovery Claims

The honest answer is that the marketing around this pairing runs well ahead of the evidence. The described mechanism is hormonal recalibration, not pharmacological sedation, and mechanism is not the same thing as a demonstrated result. Chronic stress, erratic schedules, late-night light exposure, and unmanaged sleep apnoea are independent drivers of fragmented sleep, and nothing in the cited literature suggests a peptide input overrides them.

The pathway is coherent on paper: restore the nocturnal GH pulse that age and lifestyle erode, and cortisol feedback, slow-wave sleep proportion, and repair signalling are the variables expected to shift. But when HPA output remains persistently elevated, the GH side of that feedback loop is working against a continuous input — a mechanistic limitation, not a measured failure rate, since no cited trial quantifies non-response for this combination.

This is not a criticism of the compounds. It is a statement about where the evidence currently stands. CJC-1295 and Ipamorelin remain among the most widely discussed GH secretagogues in sleep and recovery research, and the research-grade peptides in our catalogue are supplied for laboratory research only. No peptide input in a study design substitutes for controlling the sleep and circadian variables the design is meant to isolate.

Any timeline expectation for this pairing should therefore be treated as an open research question rather than a schedule. If an observation window passes without a measurable change, the variable in question may not be the compound at all — it may be what else in the model is fragmenting sleep, and whether the measurement instrument is sensitive enough to detect a change in stage distribution.

Real Peptides synthesises every compound through small-batch production with defined amino-acid sequencing for research applications. The CJC-1295 / Ipamorelin combination remains one of the most frequently studied pairings in sleep and recovery investigation — a research tool, sold for research use only and not for human consumption.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

No controlled human trial establishing a week-by-week sleep results timeline for this specific pairing is cited on this page, and the interval at which sleep-architecture changes would become measurable is not specified in the literature reviewed here. Mechanistically — and this is compound-class reasoning, not a measured outcome — GH release is a same-session event, while IGF-1 is a slower downstream marker tracked over days to weeks in GH research generally. Polysomnography, actigraphy, and salivary cortisol are the instruments such a study would use.

The recovery timeline for this combination has not been characterised in the sources available. Recovery research typically measures resting heart rate, heart rate variability, sleep efficiency, and subjective load markers, but no cited trial applies those endpoints to CJC-1295 no DAC with Ipamorelin over a defined schedule. In overtraining contexts, training load is the dominant variable and no available report isolates a peptide contribution from load management. Human data here is thin and should be described as such.

Not in the literature reviewed for this page. Figures circulating for sleep, recovery, or body-composition changes on a week-by-week basis are not traceable to a controlled trial of this pairing, so this article does not reproduce them. What can be stated is the order of events proposed mechanistically: GH pulse first, IGF-1 steady state later, with body-composition markers downstream of both. Magnitudes and intervals are not specified.

Growth hormone and cortisol sit in reciprocal feedback: GH exerts negative feedback on the hypothalamic-pituitary-adrenal axis, and elevated cortisol suppresses GH secretion. The early-morning cortisol rise is a recognised contributor to sleep fragmentation in adult sleep physiology. That is general endocrinology, not a finding about CJC-1295 no DAC or Ipamorelin; no cited study quantifies a cortisol change attributable to this combination.

CJC-1295 with DAC carries a drug affinity complex that binds plasma albumin and keeps the molecule in circulation far longer, producing sustained rather than pulsatile GH elevation. Without DAC, that modification is absent, so the analogue is short-acting and more closely tracks the natural pulse pattern. Precise half-life values and any comparative sleep endpoints are not specified in the literature cited on this page.

No. The described pathway is pituitary GH secretion through GHRH receptors and the ghrelin receptor GHS-R1a, which is pharmacologically distinct from the GABAergic and melatonergic pathways that sedative-hypnotics act on. Neither compound is classified as a central nervous system depressant in the peptide literature. Sleep physiology separately associates morning grogginess with slow-wave sleep occurring late in the sleep period, but no cited study has measured stage distribution under this combination.

Interaction data for melatonin alongside this peptide combination is not specified in the literature reviewed here. Melatonin acts on circadian timing through melatonin receptors, a pathway separate from GH secretagogue signalling, but claims that particular melatonin amounts suppress or enhance GH release under this pairing are not supported by any citation carried on this page.

No discontinuation study on this combination is cited here, so post-cessation behaviour of sleep or recovery markers is not documented. Pharmacologically, CJC-1295 without DAC is short-acting and IGF-1 is a slower-moving downstream marker, which implies clearance-driven return toward baseline endocrine values — mechanistic reasoning, explicitly labelled as such, not a measured finding. Withdrawal or rebound phenomena are not described in the sources available.

Sleep research relies on objective instrumentation rather than self-report: polysomnography for REM and slow-wave proportions, actigraphy or consumer wearables for wake episodes and sleep efficiency, salivary or serum cortisol for HPA output, and serial IGF-1 for downstream GH signalling. Blinded, placebo-controlled designs with baseline measurement periods are what separate compound effect from expectation effect. No such trial of CJC-1295 no DAC with Ipamorelin is cited on this page.

Long-term human data on GH secretagogues is limited, and the literature reviewed here does not specify a long-term safety profile for CJC-1295 no DAC combined with Ipamorelin. IGF-1 is the marker endocrine research monitors when assessing supraphysiologic elevation. These peptides are research-grade materials supplied for research use only and not for human consumption; this page makes no determination about human use.

Baseline cortisol and baseline endogenous GH output are the variables most often cited as sources of between-subject variability in GH secretagogue research generally. Pituitary responsiveness to GHRH and ghrelin mimetics also declines with age, which is standard endocrine physiology rather than a compound-specific finding. How much of the variability observed with this particular pairing traces to those factors is not quantified in the literature reviewed here.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA